Matriptase expression in the normal and neoplastic mast cells

European Journal of Dermatology

Volumn 17, Issue 5, 2007, Pages 375-380

  Cheng, Ming Fang ^a   Jin, Jong Shiaw ^a   Wu, Huang Wei ^b   Chiang, Pei Chun ^c   Sheu, Lai Fa ^a   Lee, Herng Sheng ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b Division of Neurosurgery   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Mast cell; Mastocytoma; Mastocytosis; Matriptase; Urticaria pigmentosa

Indexed keywords

CHYMASE; MATRIPTASE; SERINE PROTEINASE; TRYPTASE;

ANAPHYLACTIC SHOCK; ARTICLE; CANCER CELL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME LOCALIZATION; EPITHELIUM CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; MAST CELL; MASTOCYTOMA; MASTOCYTOSIS; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; SKIN ALLERGY; SKIN CANCER; TUMOR GROWTH; URTICARIA PIGMENTOSA;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; MALE; MAST CELLS; MASTOCYTOMA, SKIN; MASTOCYTOSIS; MIDDLE AGED; MYOMETRIUM; PROTO-ONCOGENE PROTEINS C-KIT; SERINE ENDOPEPTIDASES; UTERINE NEOPLASMS;

EID: 34548798076     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2007.0233     Document Type: Article

References (53)

1. Hooper JD, Clements JA, Quigley JP, Antalis TM. Type II transmembrane serine proteases: insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 2001; 276: 857-60.
2. Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH, Antalis TM. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 2003; 22: 237-58.
3. Szabo R, Wu Q, Dickson RB, Netzel-Arnett S, Antalis TM, Bugge TH. Type II transmembrane serine proteases. Thromb Haemost 2003; 90: 185-93.
4. List K, Bugge TH, Szabo R. Matriptase: potent proteolysis on the cell surface. Mol Med 2006; 12: 1-7.
5. Shi YE, Torri J, Yieh L, Wellstein A, Lippman ME, Dickson RB. Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res 1993; 53: 1409-15.
6. Lin CY, Anders J, Johnson M, Dickson RB. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999; 274: 18237-42.
7. Lee MS, Kiyomiya K, Benaud C, Dickson RB, Lin CY. Simultaneous activation and hepatocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells. Am J Physiol Cell Physiol 2005; 288: C932-41.
8. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36720-5.
9. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275: 26333-42.
10. Matsumori A. Roles of hepatocyte growth factor and mast cells in thrombosis and angiogenesis. Cardiovasc Drugs Ther 2004; 18: 321-6.
11. Matsumori A, Takano H, Obata JE, Takeda S, Tsuyuguchi N, Ono K, Okada M, Miyamoto T, Ohnishi T, Daikuhara Y, Sasayama S. Circulating hepatocyte growth factor as a diagnostic marker of thrombus formation in patients with cerebral infarction. Circ J 2002; 66: 216-8.
12. Hata N, Matsumori A, Yokoyama S, Ohba T, Shinada T, Yoshida H, Tokuyama K, Imaizumi T, Mizuno K. Hepatocyte growth factor and cardiovascular thrombosis in patients admitted to the intensive care unit. Circ J 2004; 68: 645-9.
13. Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY. The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem 2003; 278: 26773-9.
14. Comoglio PM, Boccaccio C. Scatter factors and invasive growth. Semin Cancer Biol 2001; 11: 153-65.
15. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
16. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53: 2513-21.
17. Eichbaum MH, de Rossi TM, Kaul S, Bruckner T, Schneeweiss A, Sohn C. Serum Levels of Hepatocyte Growth Factor/Scatter Factor in Patients with Liver Metastases from Breast Cancer. Tumour Biol 2006; 28: 36-44.
18. Jin X, Hirosaki T, Lin CY, Dickson RB, Higashi S, Kitamura H, Miyazaki K. Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin. J Cell Biochem 2005; 95: 632-47.
19. Satomi S, Yamasaki Y, Tsuzuki S, Hitomi Y, Iwanaga T, Fushiki T. A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover. Biochem Biophys Res Commun 2001; 287: 995-1002.
20. Hallgren J, Pejler G. Biology of mast cell tryptase. An inflammatory mediator. FEBS J 2006; 273: 1871-95.
21. Omoto Y, Tokime K, Yamanaka K, Habe K, Morioka T, Kurokawa I, Tsutsui H, Yamanishi K, Nakanishi K, Mizutani H. Human mast cell chymase cleaves pro-IL-18 and generates a novel and biologically active IL-18 fragment. J Immunol 2006; 177: 8315-9.
22. Buckley MG, McEuen AR, Walls AF. The detection of mast cell subpopulations in formalin-fixed human tissues using a new monoclonal antibody specific for chymase. J Pathol 1999; 189: 138-43.
23. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005; 280: 9291-6.
24. Naesse EP, Schreurs O, Helgeland K, Schenck K, Steinsvoll S. Matrix metalloproteinases and their inhibitors in gingival mast cells in persons with and without human immunodeficiency virus infection. J Periodontal Res 2003; 38: 575-82.
25. Dinh QT, Cryer A, Trevisani M, Dinh S, Wu S, Cifuentes LB, Feleszko WK, Williams A, Geppetti P, Fan Chung K, Heppt W, Klapp BF, Fischer A. Gene and protein expression of protease-activated receptor 2 in structural and inflammatory cells in the nasal mucosa in seasonal allergic rhinitis. Clin Exp Allergy 2006; 36: 1039-48.
26. Thomas VA, Wheeless CJ, Stack MS, Johnson DA. Human mast cell tryptase fibrinogenolysis: kinetics, anticoagulation mechanism, and cell adhesion disruption. Biochemistry 1998; 37: 2291-8.
27. He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 2004; 10: 309-18.
28. Rojas IG, Spencer ML, Martinez A, Maurelia MA, Rudolph MI. Characterization of mast cell subpopulations in lip cancer. J Oral Pathol Med 2005; 34: 268-73.
29. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST. Mast cells and cutaneous malignancies. Mod Pathol 2006; 19: 149-59.
30. Cabanillas-Saez A, Schalper JA, Nicovani SM, Rudolph MI. Characterization of mast cells according to their content of tryptase and chymase in normal and neoplastic human uterine cervix. Int J Gynecol Cancer 2002; 12: 92-8.
31. Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B, Bajdik C, Gelmon K, Chia S, Hayes M. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol 2004; 17: 690-5.
32. Cheng MF, Tzao C, Tsai WC, Lee WH, Chen A, Chiang H, Sheu LF, Jin JS. Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: Correlation with clinicopathological parameters. Dis Esophagus 2006; 19: 482-6.
33. Oberst MD, Singh B, Ozdemirli M, Dickson RB, Johnson MD, Lin CY. Characterization of matriptase expression in normal human tissues. J Histochem Cytochem 2003; 51: 1017-25.
34. List K, Szabo R, Molinolo A, Nielsen BS, Bugge TH. Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am J Pathol 2006; 168: 1513-25.
35. Hung RJ. Hsu laW, Dreiling JL, Lee MJ, Williams CA, Oberst MD, Dickson RB, Lin CY. Assembly of adherens junctions is required for sphingosine 1-phosphate-induced matriptase accumulation and activation at mammary epithelial cell-cell contacts. Am J Physiol Cell Physiol 2004; 286: C1159-69.
36. Benaud C, Oberst M, Hobson JP, Spiegel S, Dickson RB, Lin CY. Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase. J Biol Chem 2002; 277: 10539-46.
37. Kiyomiya KI, Lee MS, Tseng IC, Zuo H, Barndt RJ, Johnson MD, Dickson RB, Lin CY. Matriptase activation and subsequent shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells. Am J Physiol Cell Physiol 2006; 291: C40-9.
38. Kilpatrick LM, Harris RL, Owen KA, Bass R, Ghorayeb C, Bar-Or A, Ellis V. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood 2006; 108: 2616-23.
39. Seitz I, Hess S, Schulz H, Eckl R, Busch G, Montens HP, Brandl R, Seidl S, Schomig A, Ott I. Membrane-Type Serine Protease-1/Matriptase Induces Interleukin-6 and -8 in Endothelial Cells by Activation of Protease-Activated Receptor-2. Potential Implications in Atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 769-75.
40. Jin X, Yagi M, Akiyama N, Hirosaki T, Higashi S, Lin CY, Dickson RB, Kitamura H, Miyazaki K. Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci 2006; 97: 1327-34.
41. Krishnaswamy G, Kelley J, Johnson D, Youngberg G, Stone W, Huang SK, Bieber J, Chi DS. The human mast cell: functions in physiology and disease. Front Biosci 2001; 6: D1109-27.
42. Payne V, Kam PC. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia 2004; 59: 695-703.
43. Matsumori A. Roles of hepatocyte growth factor and mast cells in thrombosis and angiogenesis. Cardiovasc Drugs Ther 2004; 18: 321-6.
44. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77: 1033-79.
45. Montesano R, Matsumoto K, Nakamura T, Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991; 67: 901-8.
46. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992; 119: 629-41.
47. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, Polverini P, Rosen EM. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993; 90: 1937-41.
48. Schwartz LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res 2001; 25: 553-62.
49. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 4660-6.
50. Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. Cancer 2006; 107: 1429-39.
51. Barbie DA, Deangelo DJ. Systemic mastocytosis: current classification and novel therapeutic options. Clin Adv Hematol Oncol 2006; 4: 768-75.
52. Crowe SE, Luthra GK, Perdue MH. Mast cell mediated ion transport in intestine from patients with and without inflammatory bowel disease. Gut 1997; 41: 85-92.
53. Schwarz T. Dermatology and basic science. Eur J Dermatol 2007; 17: 182-4.